NEW YORK: equities started the three-week reporting period to January 2 in positive mode, on dovish remarks from the Federal Reserve Bank, then drifted around to end in negative territory, with the Dow Jones a slight 0.3% lower overall. Bond market developments raised uncertainty about the US economy in the last trading week of 2005. January 2 was a holiday. Drug and biotechnology stocks were mixed with 22 of those tracked falling and a like number rising.
Of the drug majors, Pfizer, which ended up 11.4%, also boosted the drug sector as a whole on December 19 after its important patent battle win on Lipitor (atorvastatin) against India's Ranbaxy (see page 5). Pfizer also cheered investors by raising its dividend 26% to $0.24, after its recent stock slide. Merck & Co, which rose 12% over the period, was helped by its cost-cutting plans and R&D presentation, aimed at regained drug sector leadership (see page 3) as well as Pfizer's victory, as it too is facing patent challenges. Additionally, Morgan Stanley raised its price target on Merck's stock to $32.28. Also benefiting for the same reason was Bristol-Myers Squibb, up 7.7%. Medarex' stock rocketed 36.6% on speculation the company might be bought following Amgen's acquisition of Abgenix, as both Medarex and Abgenix are developing cancer-antibody agents in partnership with larger drug companies. Ken Kulju of Credit Suisse First Boston has maintained his neutral rating on Cephalon, which rose 16% on the reporting week, after the firm, along with Alkermes, received an approvable letter for Vivitrol (naltrexone). The firms plan to debut the alcohol dependency drug in the second quarter of this year. Sales in 2006 should be $30.0 million, ramping up to around $77.0 million in 2007, he said.
Looking to the new year, Al Rausch of AG Edwards expects that drug companies will benefit from implementation of the new Prescription Drug Benefit Plan, which will significantly reduce political pressure to introduce a program that allows drug reimportation. He also expects a continued heightened concern over drug safety and more "black box" warning requirements from the Food and Drug Administration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
An ophthalmic gene therapy company aiming to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
Stock Commentary - New York week to Jan 9
NEW YORK: equities started the three-week reporting period to January 2 in positive mode, on dovish remarks from the Federal Reserve Bank, then drifted around to end in negative territory, with the Dow Jones a slight 0.3% lower overall. Bond market developments raised uncertainty about the US economy in the last trading week of 2005. January 2 was a holiday. Drug and biotechnology stocks were mixed with 22 of those tracked falling and a like number rising.
Of the drug majors, Pfizer, which ended up 11.4%, also boosted the drug sector as a whole on December 19 after its important patent battle win on Lipitor (atorvastatin) against India's Ranbaxy (see page 5). Pfizer also cheered investors by raising its dividend 26% to $0.24, after its recent stock slide. Merck & Co, which rose 12% over the period, was helped by its cost-cutting plans and R&D presentation, aimed at regained drug sector leadership (see page 3) as well as Pfizer's victory, as it too is facing patent challenges. Additionally, Morgan Stanley raised its price target on Merck's stock to $32.28. Also benefiting for the same reason was Bristol-Myers Squibb, up 7.7%. Medarex' stock rocketed 36.6% on speculation the company might be bought following Amgen's acquisition of Abgenix, as both Medarex and Abgenix are developing cancer-antibody agents in partnership with larger drug companies. Ken Kulju of Credit Suisse First Boston has maintained his neutral rating on Cephalon, which rose 16% on the reporting week, after the firm, along with Alkermes, received an approvable letter for Vivitrol (naltrexone). The firms plan to debut the alcohol dependency drug in the second quarter of this year. Sales in 2006 should be $30.0 million, ramping up to around $77.0 million in 2007, he said.
Looking to the new year, Al Rausch of AG Edwards expects that drug companies will benefit from implementation of the new Prescription Drug Benefit Plan, which will significantly reduce political pressure to introduce a program that allows drug reimportation. He also expects a continued heightened concern over drug safety and more "black box" warning requirements from the Food and Drug Administration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze